Table 1.
Demographic and Clinical Characteristics
| Baseline Characteristics | PrEP Group (n = 124) | Placebo Group (n = 123) |
|---|---|---|
| HIV-1–uninfected participant | ||
| Male sex, No. (%) | 80 (65) | 82 (67) |
| Age, median (IQR), y | 28 (24–35) | 30 (25–35) |
| Educational level, median (IQR), y | 8 (6–11) | 8 (5–12) |
| No. of sex acts in prior month, median (IQR) | 5 (3–8) | 4 (3–8) |
| Any unprotected sex in prior month, No. (%) | 60 (49) | 65 (55) |
| HIV-1–infected partner | ||
| CD4+ T-cell count, median (IQR), cells/µL | 549 (432–728) | 536 (387–654) |
| HIV-1 RNA load in plasma, median (IQR), log10 copies/mL | 4.4 (3.7–4.9) | 4.6 (4–5) |
| WHO stage, No. (%) | ||
| 1 | 64 (52) | 65 (53) |
| 2 | 46 (37) | 39 (32) |
| 3 | 14 (11) | 19 (15) |
| Couple, median (IQR) | ||
| Partnership duration, y | 3 (1–6) | 4 (1–8) |
| No. of children together | 1 (0–2) | 1 (0–2) |
Abbreviations: HIV, human immunodeficiency virus; IQR, interquartile range; PrEP, preexposure prophylaxis; WHO, World Health Organization.